How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...

Strip bonds, also known as zero-coupon bonds, are securities where principal and coupon payments are separated and sold individually. They carry no reinvestment risk since the face value is paid only ...

Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Amanda Jackson has expertise in personal ...